A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: A multicenter national study in Japan

Hepatology International

Volumn 3, Issue 3, 2009, Pages 468-479

  Iwasaki, Yoshiaki ^a   Shiratori, Yasushi ^a   Hige, Shuhei ^b   Nishiguchi, Shuhei ^c   Takagi, Hitoshi ^d   Onji, Morikazu ^e   Yoshida, Haruhiko ^f   Izumi, Namiki ^g   Kohgo, Yutaka ^h   Yamamoto, Kyosuke ⁱ   Sato, Nobuhiro ^j   Shibuya, Akitaka ^k   Saito, Hidetsugu ^l   Sata, Michio ^m   Suzuki, Kazuyuki ⁿ   Kaneko, Shuichi ^o   Moriyama, Mitsuhiko ^p   Omata, Masao ^f  

^a OKAYAMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g MUSASHINO RED CROSS HOSPITAL   (Japan)

^h ASAHIKAWA MEDICAL COLLEGE   (Japan)

ⁱ SAGA UNIVERSITY   (Japan)

^j JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KITASATO UNIVERSITY HOSPITAL   (Japan)

^l KEIO UNIVERSITY   (Japan)

^m KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ IWATE MEDICAL UNIVERSITY   (Japan)

^o KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^p NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chronic hepatitis C; Genotype 2; Peginterferon monotherapy; Pretreatment viral load; Randomized trial; Rapid virological response

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAPID VIROLOGICAL RESPONSE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 68949152547     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9134-1     Document Type: Article

References (34)

1. El Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-823.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52. doi: 10.1056/NEJM200107053450107.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46. doi: 10.1002/hep.1840360706.
4. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
5. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-1695. doi: 10.1002/hep.510280632.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982. doi: 10.1056/NEJMoa020047.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965. doi: 10.1016/ S0140-6736(01)06102-5.
9. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001;285:193-199. doi: 10.1001/ jama.285.2.193.
10. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1499. doi: 10.1056/NEJM199811193392102.
11. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. Br Med J 2001;323:1151-1155. doi: 10.1136/bmj.323.7322.1151.
12. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19(Suppl 1):67-75.
13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492. doi: 10.1056/NEJM199811193392101.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432. doi: 10.1016/S0140-6736(98)07124-4.
15. Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63. doi: 10.1002/ hep.20984.
16. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680. doi: 10.1056/ NEJM200012073432302.
17. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403. doi: 10.1053/jhep.2001.26371.
18. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672. doi: 10.1056/NEJM200012073432301.
19. Data on file. PEGASYS. Tokyo (Japan): Chugai Pharmaceuticals Inc; 2002.
20. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-679. doi: 10.1099/0022-1317-73-3-673.
21. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-1353. doi: 10.1002/ hep.1840190605.
22. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558-566. doi: 10.1053/gast.1997.v113.pm9247476.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293. doi: 10.1002/hep.510240201.
24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520. doi: 10.1002/hep.1840190629.
25. Sakai T, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. High response rates with peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive Japanese chronic hepatitis C patients: A randomized, double-blind, multicenter phase III trial. Gastroenterology 2006;130(Suppl):A839. abstract.
26. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264. doi: 10.1053/j.gastro.2005.11.010.
27. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-1845. doi: 10.1002/hep.22253.
28. Shiffman ML, Suter F, Bacon B, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134. doi: 10.1056/NEJMoa066403.
29. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
30. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559. doi: 10.1136/ gut.2006.102558.
31. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42. doi: 10.1002/ hep.21975.
32. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732. doi: 10.1053/j.gastro.2004.09.050.
33. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609. doi: 10.1053/jhep.2003.50106.
34. Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, et al. Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. J Gastroenterol Hepatol 2008;23:541-545. doi: 10.1111/j.1440-1746.2008.05356.x.